The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during hospitalization in one of the participating departments, between patients treated with ceftriaxone and patients treated with cefotaxime

Inclusion Criteria:

• Age ≥ 18 years old
• Indication for antibiotic treatment with a 3rd generation injectable cephalosporin (cefotaxime or ceftriaxone)
• Signed Informed Consent

Exclusion Criteria:

• Hypersensitivity to ceftriaxone or cefotaxime, to another cephalosporin or to any of the excipients of the specialities concerned.
• History of severe hypersensitivity (e.g., anaphylactic reaction) to another class of antibacterial agent of the beta-lactam family (penicillins, monobactams and carbapenes)
• Subcutaneous administration of ceftriaxone
• Pregnant and breastfeeding woman
• Suspicion of Pseudomonas infection or documented Pseudomonas infection requiring ceftazidime treatment
• Suspicion of group III enterobacteriaceae infection or group III enterobacteriaceae infection requiring cefepime treatment